• Cannara expanded its two-year international supply agreement with Curaleaf International, lifting potential aggregate contract value to about C$34 million.
• Prior terms implied up to C$21 million, based on committed supply volumes plus contract conditions.
• Flower supplied under the deal will be dried and processed under EU-GMP conditions at Curaleaf’s EU-GMP certified Canadian facility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannara Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONECNPR____9838830) on October 05, 2026, and is solely responsible for the information contained therein.